Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study

  Study patients N = 11
Male sex, n (%) 11 (100)
Age (years) a 35 (32–45)
Body weight (kg) a 56.1 (51.6–67.3)
BMI (kg/m2) a 18.2 (17.6–22.8)
BSA (m2) 1.69 (1.60–1.79)
Serum creatinine (mg/dL) a 0.80 (0.70–0.80)
eGFR (mL/min · 1.73 m2) a 96.1 (81.9–103.1)
CKD stage, n (%)  
1 7 (63.6)
2 4 (36.4)
3 0 (0)
4 0 (0)
5 0 (0)
CD4+ cell count (/μL) a 119 (37–211)
HIV RNA viral load (log10/mL) a 4.83 (4.61–5.85)
Protease inhibitors (ritonavir-boosted), n (%) 7 (63.6)
Protease inhibitors (unboosted), n (%) 0 (0)
NNRTIs, n (%) 0 (0)
INSTIs, n (%) 4 (36.4)
Concurrent use of a nephrotoxic drug, n (%) 4 (36.4)
Hypertension, n (%) 0 (0)
Diabetes, n (%) 0 (0)
Hepatitis B, n (%) 3 (27.3)
Hepatitis C, n (%) 0 (0)
Plasma TFV concentration (ng/mL) a 64.0 (56.0–90.5)
  1. BMI body mass index, BSA body surface area, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, NNRTIs non-nucleoside reverse-transcriptase inhibitors, INSTIs integrase strand transfer inhibitors, TFV tenofovir
  2. aValues are reported as median (interquartile range)